Department of Endocrinology (Austin Health), Heidelberg, University of Melbourne, Victoria, Australia.
Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia.
J Clin Endocrinol Metab. 2021 Mar 25;106(4):942-951. doi: 10.1210/clinem/dgaa873.
Preclinical data has shown progesterone metabolites improve sleep parameters through positive allosteric modulation of the γ-aminobutyric acid type A receptor. We undertook a systematic review and meta-analysis of randomized controlled trials to assess micronized progesterone treatment on sleep outcomes.
Using preferred reporting items for systematic review and meta-analysis guidelines, we searched MEDLINE, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials for randomized controlled trials of micronized progesterone treatment on sleep outcomes up to March 31, 2020. This study is registered with the International Prospective Register of Systematic Reviews, number CRD42020165981. A random effects model was used for quantitative analysis.
Our search strategy retrieved 9 randomized controlled trials comprising 388 participants. One additional unpublished trial was found. Eight trials enrolled postmenopausal women. Compared with placebo, micronized progesterone improved various sleep parameters as measured by polysomnography, including total sleep time and sleep onset latency, though studies were inconsistent. Meta-analysis of 4 trials favored micronized progesterone for sleep onset latency (effect size, 7.10; confidence interval [CI] 1.30, 12.91) but not total sleep time (effect size, 20.72; CI -0.16, 41.59) or sleep efficiency (effect size, 1.31; CI -2.09, 4.70). Self-reported sleep outcomes improved in most trials. Concomitant estradiol administration and improvement in vasomotor symptoms limit conclusions in some studies.
Micronized progesterone improves various sleep outcomes in randomized controlled trials, predominantly in studies enrolling postmenopausal women. Further research could evaluate the efficacy of micronized progesterone monotherapy using polysomnography or validated questionnaires in larger cohorts.
临床前数据表明,孕激素代谢物通过对γ-氨基丁酸 A 型受体的正变构调节改善睡眠参数。我们进行了一项系统评价和荟萃分析,以评估微粒化黄体酮治疗对睡眠结果的影响。
使用系统评价和荟萃分析指南的首选报告项目,我们在 MEDLINE、Embase、PsycInfo 和 Cochrane 对照试验中心注册库中搜索了截至 2020 年 3 月 31 日关于微粒化黄体酮治疗睡眠结果的随机对照试验。本研究在国际前瞻性系统评价注册中心注册,编号为 CRD42020165981。采用随机效应模型进行定量分析。
我们的检索策略共检索到 9 项随机对照试验,包括 388 名参与者。还发现了一项额外的未发表试验。8 项试验纳入了绝经后妇女。与安慰剂相比,微粒化黄体酮改善了多导睡眠图测量的各种睡眠参数,包括总睡眠时间和睡眠潜伏期,但研究结果不一致。对 4 项试验的荟萃分析有利于微粒化黄体酮治疗睡眠潜伏期(效应大小,7.10;置信区间 [CI] 1.30,12.91),但对总睡眠时间(效应大小,20.72;CI-0.16,41.59)或睡眠效率(效应大小,1.31;CI-2.09,4.70)则不然。大多数试验中自我报告的睡眠结果得到了改善。在一些研究中,伴随的雌二醇给药和血管舒缩症状的改善限制了结论。
微粒化黄体酮在随机对照试验中改善了各种睡眠结果,主要是在纳入绝经后妇女的研究中。进一步的研究可以使用多导睡眠图或经过验证的问卷在更大的队列中评估微粒化黄体酮单药治疗的疗效。